• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    2/9/23 11:07:44 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email
    SC 13G/A 1 tv0313-arrowheadpharmaceutic.htm SCHEDULE 13G/A arrowheadpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Arrowhead Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  04280A100

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  04280A100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    176,634

    7.  SOLE DISPOSITIVE POWER

    10,005,222

    8.  SHARED DISPOSITIVE POWER

    280,950

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,286,172

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.70%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Arrowhead Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    177 East Colorado Boulevard, Suite 700
    Pasadena, CA 91105

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    04280A100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ARWR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARWR

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    More analyst ratings

    $ARWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Arrowhead with a new price target

      Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

      6/5/24 7:11:50 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Arrowhead with a new price target

      BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00

      12/4/23 7:19:37 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Arrowhead with a new price target

      Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00

      9/19/23 7:26:13 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

      SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      11/14/24 9:38:25 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      10/16/24 9:15:20 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      4/10/24 2:03:52 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    SEC Filings

    See more
    • Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      4/15/25 3:50:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by Arrowhead Pharmaceuticals Inc.

      424B7 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      3/7/25 4:15:52 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by Arrowhead Pharmaceuticals Inc.

      SCHEDULE 13D - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      2/14/25 5:23:17 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Financials

    Live finance-specific insights

    See more
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

      4/30/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

      - Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for

      2/10/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will

      1/22/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/20/24 7:06:58 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      4/11/25 6:20:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard was granted 340,000 shares and sold $774,975 worth of shares (51,425 units at $15.07), increasing direct ownership by 8% to 4,062,377 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/17/25 5:45:33 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard sold $5,274,334 worth of shares (300,000 units at $17.58) and exercised 300,000 shares at a strike of $7.75 (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/5/25 6:32:06 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using

      5/7/25 7:30:00 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

      4/30/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Leadership Updates

    Live Leadership Updates

    See more
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

      NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

      1/22/25 5:54:00 PM ET
      $APO
      $ARWR
      $B
      $GWRE
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)